Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGN1601
- Development stage
- Phase 2
- Lead developer
- Mologen
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
**MGN1601** is an investigational, fixed-combination therapeutic cancer vaccine developed by Mologen for advanced renal cell carcinoma. It combines allogeneic human renal cancer cells genetically modified with MIDGE DNA vectors to express interleukin-7, granulocyte-macrophage colony-stimulating factor, CD80, and CD154, with dSLIM, a DNA-based Toll-like receptor 9 agonist. The product is intended to promote innate and adaptive antitumor immunity against renal-cell-carcinoma-associated antigens and was evaluated by intradermal administration in the Phase 1/2 ASET study.
- Other names
- ASET vaccine
02
Targets
CD28 (Cluster of Differentiation 28)CD40 (Cluster of differentiation 40 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)IL7R (Interleukin-7 Receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on MGN1601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGN1601.